Your university hospital in the heart of Munich

We are the **Klinikum rechts der Isar (MRI) Hospital of Munich Technical University (TUM**) and a reliable employer of around 6,000 people. Being a university hospital, we not only look after our patients but, based on our motto "Knowledge Creates Cures" (*Wissen schafft Heilung*), we are also engaged in research and teaching, enjoying an excellent national as well as international reputation. 160 different professional groups work hand in hand to ensure that our patients receive the best possible treatment.

As of May 2021 the **Department and Clinical Research Facility for Neuroproteomics** of the Klinikum rechts der Isar Hospital of Munich Technical University is looking for a

Postdoctoral researcher (f/m/d) in Proteomics – Mass spectrometry

Description of research and laboratory:

The research team of professor Stefan Lichtenthaler studies the molecular mechanisms underlying Alzheimer's disease, with a focus on microglia and cell surface proteases, such as BACE1, which is a major drug target. Our lab is equipped with state-of-the-art mass spectrometry systems: a Q-Exactive, a Q-Exactive HF, and a timsTOF Pro mass spectrometer. We offer excellent and exciting projects and are part of several larger research consortia in Munich (e.g. DFG-funded excellence cluster SyNergy and Clinspect-M) and of the German Center for Neurodegenerative Diseases (DZNE) in Munich-Großhadern, a national Center for Excellence in neurodegeneration.

The position:

You will optimize proteomic sample preparation and mass spectrometry acquisition methods for high-throughput analysis of cerebrospinal fluid, brain tissue, and primary cell culture secretome analyses. Your position is part of the large proteomic Clinspect-M consortium in Munich, in which we want to bring mass-spectrometry-based proteomics into clinical routine with the aim of fast biomarker measurements from human body fluids. Additionally, you will be involved in the maintenance of our nanoLC-MS/MS systems.

Requirements:

You have a PhD in proteomics, biochemistry, molecular biology or a related field. You have hands-on experience with proteomics and with nanoLC-MS/MS systems and with proteomic data analysis. Experience with biochemical protein assays, such as Western blots, ELISA and cell culture assays, is an advantage. Flexibility and the ability to work in a multidisciplinary environment and on parallel projects are essential. You do not need to have previous knowledge about Alzheimer's disease or neurodegeneration. You are creative, self-motivated and able to work independently and are fluent in English.

We offer you:

- A varied and professionally demanding position in a state-of-the-art working environment

- Appointment is full time (38.5 weekly working hours) and will be initially for two years with the possibility of renewal.

- Performance-related salary in accordance with the TV-L public-sector salary scale plus attractive benefits offered to public- sector employees

If the candidates' suitability for the position in question is equal, severely disabled applicants shall be given preference. Interview-related costs can, unfortunately, not be reimbursed.

Applications including motivation letter, CV, publication list and two recommendation letters or references should be sent as a single document via e-mail to: Anke.Moeller@dzne.de

Prof. Dr. Stefan Lichtenthaler
Department and Clinical Research Facility for Neuroproteomics
Klinikum rechts der Isar Hospital of Munich Technical University
Feodor-Lynen-Strasse 17
81377 München

Selected References:

Colombo and Dinkel, et al. (2021) Nat Commun., Feb 24;12(1):1158

Tüshaus et al. (2020) EMBO J. Oct 15;39(20):e105693.

Sebastian Monasor and Müller et al. (2020) Elife, Jun 8;9:e54083

Cunha et al. (2020) J Exp Med., 217(5):e20191390

Brummer et al. (2019) EMBO Mol Med, 11, e9695. / Colombo et al. (2018) EMBO J, 37, e97390.

Herber et al. (2018) Mol Cell Proteomics, 17, 1487. / Pigoni et al. (2016) Mol Neurodegeneration, 11, 67.

Barao et al. (2016) Trends in Neurosci, 39, 158. / Kuhn PH et al. (2012) EMBO J 31, 3157.